^
Association details:
| Biomarker: | ER Y537S + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | H3B-6545 (Selective estrogen receptor α inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer
Published date:
11/17/2020
Excerpt:
...pts with ER+, HER2-metastatic breast cancer, including 12 pts harboring high allele frequency clonal ESR1 Y537S circulating tumor DNA (ctDNA)...H3B-6545 demonstrated promising clinical activity among these pts with clonal Y537S mutations, with a median progression free survival of 7.3 months and an overall response rate of 25% (3 confirmed partial responses).
Trial ID:
